Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer (NCT05403385)
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy
🩺 Plain-English Summary (8th-Grade Level)
The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or metastatic non-small cell lung cancer. The efficacy and safety of the combination is then compared to standard of care carboplatin and pemetrexed in the same populations.
Who can join: Review the eligibility criteria below.
Location: Highlands Oncology Group — Fayetteville, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- Highlands Oncology Group — Fayetteville, Arkansas
- H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
- Algemeen Ziekenhuis Sint-Lucas — Ghent,
- Jessa Ziekenhuis — Hasselt,
- AZ Delta — Roeselare,
- William Osler Health System — Brampton, Ontario
- Vseobecna Fakultni Nemocnice — Prague,
- CHU de Caen — Caen,
- Hopital de la Timone Centre d'Essais Précoces en Cancérologie de Marseille (CEPCM) — Marseille,
- CHU Nantes — Nantes,
- Istituto Nazionale dei Tumori — Milan,
- Gruppo Humanitas - Istituto Clinico Humanitas — Rozzano,
- Hospital Universitari Son Espases — Palma de Mallorca, Balearic Islands
- Complejo Hospitalario de Navarra (CHN) — Pamplona, Pamplona
- Hospital Universitari i Politecnic La Fe de Valencia — Valencia, Valencia
- Centro Oncologico de Galicia — A Coruña,
- Hospital Infanta Cristina (Hospital Universitario de Badajoz) — Badajoz,
- Hospital Universitario Vall d'Hebron — Barcelona,
- Althaia Hospital — Manresa,
- Complejo Hospitalario Universitario de Ourense — Ourense,
- Centre Hospitalier Universitaire Vaudois — Lausanne,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic NSCLC - Non-Small Cell Lung Cancer
- ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI) — Toronto, Ontario
Explore by condition: All Metastatic NSCLC - Non-Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.